{
  "source": "PA-Med-Nec-Migraine-Migranal-Ergomar-Trudhesa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2125-10\nProgram Prior Authorization/Medical Necessity\nMedication Dihyroergotamine nasal spray (Migranal®)*, Ergomar® (ergotamine),\nTrudhesa®* (dihydroergotamine nasal spray)\nP&T Approval Date 4/2017, 6/2017, 3/2018, 3/2019, 1/2020, 1/2021, 11/2021, 11/2022,\n11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nMigranal* (dihydroergotamine) and Trudhesa* (dihydroergotamine) are indicated for the\nacute treatment of migraine headaches with or without aura. Neither Migranal* nor\nTrudhesa* are intended for the prophylactic therapy of migraine or for the management of\nhemiplegic or basilar migraine.\nErgomar is indicated to abort or prevent vascular headache, for example, migraine, migraine\nvariants or a so-called \"histaminic cephalalgia”. Ergomar should not be used for chronic\ndaily administration.\nThe American Headache Society consensus statement recommends use of nonsteroidal anti-\ninflammatory drugs (NSAIDs), nonopioid analgesics, acetaminophen, or caffeinated\nanalgesic combinations (e.g., aspirin + acetaminophen + caffeine) for mild-to-\nmoderate attacks and migraine-specific agents (triptans, dihydroergotamine [DHE], small-\nmolecule CGRP receptor antagonists, selective serotonin (5- HT1F) receptor agonist for\nmoderate or severe attacks and mild-to- moderate attacks that respond poorly to nonspecific\ntherapy.\nThis program requires a member to try one oral triptan and two nasal triptans prior to\nreceiving coverage for nasal dihydroergotamine or two oral triptans prior to receiving\ncoverage of Ergomar.\n2. Coverage Criteriaa:\nA. Dihydroergotamine Nasal Spray (Migranal*) or Trudhesa* will be approved\nbased on all of the following criteria:\n1. Diagnosis of moderate to severe migraine headaches with or without aura.\n-AND-\n2. History of failure (after at least 3 migraine episodes and a minimum of a 30-day\ntrial), contraindication, or intolerance to one of the following oral triptans\n(Document duratio",
    "without aura.\n-AND-\n2. History of failure (after at least 3 migraine episodes and a minimum of a 30-day\ntrial), contraindication, or intolerance to one of the following oral triptans\n(Document duration of trial):\na. almotriptan (Axert®)\nb. eletriptan (Relpax®)\n© 2024 UnitedHealthcare Services, Inc.\nc. frovatriptan (Frova®)\nd. naratriptan (Amerge®)\ne. rizatriptan (Maxalt®/Maxalt-MLT®)\nf. sumatriptan (Imitrex®)\ng. zolmitriptan (Zomig®)\n-AND-\n3. History of failure (after at least 3 migraine episodes and a minimum of a 30-day\ntrial), contraindication, or intolerance to both of the following:\na. sumatriptan nasal spray (generic Imitrex nasal spray)\nb. Zomig nasal spray (zolmitriptan)\nB. Ergomar (ergotamine) will be approved based on all of the following criteria:\n1. Diagnosis of moderate to severe migraine headaches with or without aura.\n-AND-\n2. History of failure (after at least 3 migraine episodes and a minimum of a 30-day\ntrial), contraindication, or intolerance to two of the following oral triptans\n(Document duration of trial):\na. almotriptan (Axert)\nb. eletriptan (Relpax)\nc. frovatriptan (Frova)\nd. naratriptan (Amerge)\ne. rizatriptan (Maxalt/Maxalt MLT)\nf. sumatriptan (Imitrex)\ng. zolmitriptan (Zomig)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n* Brand Migranal and Trudhesa are typically excluded from coverage.\n3. Additional Clinical Programs:\n• Supply limits may apply.\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n© 2024 UnitedHealthcare Services, Inc.\n4. References:\n1. Migranal [package insert]. Bridgewater, NJ: Bausch Hea",
    "automated approval and re-approval processes varies by program\nand/or therapeutic class.\n© 2024 UnitedHealthcare Services, Inc.\n4. References:\n1. Migranal [package insert]. Bridgewater, NJ: Bausch Health US, LLC.; September 2022.\n2. Ergomar [package insert]. Deerfield, IL; TerSera Therapeutics; February 2020.\n3. Trudhesa [package insert]. Seattle, WA: Impel NeuroPharma Inc; August 2023.\n3. The American Headache Society Consensus Statement: Update on integrating new migraine\ntreatments into clinical practice. Headache. 2021: 61 1021-39.\nProgram Prior Authorization/Medical Necessity – Dihydroergotamine nasal spray\nChange Control\nDate Change\n4/2017 New program.\n6/2017 Added Ergomar to criteria. State mandate reference language updated.\n3/2018 Added documentation of drug name and date of trials into the criteria.\n3/2019 Annual review. Modified documentation language, added statement\nregarding use of automated process and updated references.\n1/2020 Removed Zomig which became non-preferred. Updated references.\n1/2021 Annual review, updated references.\n11/2021 Added Trudhesa. Updated the trial language to include 3 migraine\nepisodes or a minimum of 30 days. Added Zomig nasal spray to\nrequirement for dihydroergotamine nasal spray products.\n11/2022 Annual review. Added Trudhesa typically excluded from coverage.\nUpdated references.\n11/2023 Annual review. Updated background section and references.\n11/2024 Annual review. Updated references.\n© 2024 UnitedHealthcare Services, Inc."
  ]
}